CoChat

Unlocking de novo antibody design with generative artificial intelligence

Open access
Shanehsazzadeh, Amir, McPartlon, Matt, Kasun, George, Steiger, Andrea K., Sutton, John M., Yassine, Edriss, McCloskey, Cailen, Haile, Robel, Shuai, Richard, Alverio, Julian, Rakocevic, Goran, Levine, Simon, Cejovic, Jovan, Gutierrez, Jahir M., Morehead, Alex, Dubrovskyi, Oleksii, Chung, Chelsea, Luton, Breanna K., Diaz, Nicolas, Kohnert, Christa, Consbruck, Rebecca, Carter, Hayley, LaCombe, Chase, Bist, Itti, Vilaychack, Phetsamay, Anderson, Zahra, Xiu, Lichen, Bringas, Paul, Alarcon, Kimberly, Knight, Bailey, Radach, Macey, Bateman, Katherine, Kopec-Belliveau, Gaelin, Chapman, Dalton, Bennett, Joshua, Ventura, Abigail B., Canales, Gustavo M., Gowda, Muttappa, Jackson, Kerianne A., Caguiat, Rodante, Brown, Amber, Ganini da Silva, Douglas, Guo, Zheyuan, Abdulhaqq, Shaheed, Klug, Lillian R., Gander, Miles, Yapici, Engin, Meier, Joshua, Bachas, Sharrol · 2023 · bioRxiv (Cold Spring Harbor Laboratory)
PreprintCited by 82

The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.

Abstract

Generative AI has the potential to redefine the process of therapeutic antibody discovery. In this report, we describe and validate deep generative models for the de novo design of antibodies against human epidermal growth factor receptor (HER2) without additional optimization. The models enabled an efficient workflow that combined in silico design methods with high-throughput experimental techniques to rapidly identify binders from a library of ∼10 6 heavy chain complementarity-determining region (HCDR) variants. We demonstrated that the workflow achieves binding rates of 10.6% for HCDR3 and 1.8% for HCDR123 designs and is statistically superior to baselines. We further characterized 421 diverse binders using surface plasmon resonance (SPR), finding 71 with low nanomolar affinity similar to the therapeutic anti-HER2 antibody trastuzumab. A selected subset of 11 diverse high-affinity binders were functionally equivalent or superior to trastuzumab, with most demonstrating suitable developability features. We designed one binder with ∼3x higher cell-based potency compared to trastuzumab and another with improved cross-species reactivity 1 . Our generative AI approach unlocks an accelerated path to designing therapeutic antibodies against diverse targets.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1101/2023.01.08.523187

Cites

27 of 27 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 27 references

Cited by

See all 82

Metadata

Authors
Shanehsazzadeh, A., McPartlon, M., Kasun, G., Steiger, A. K., Sutton, J. M., Yassine, E., McCloskey, C., Haile, R., Shuai, R., Alverio, J., Rakocevic, G., Levine, S., Cejovic, J., Gutierrez, J. M., Morehead, A., Dubrovskyi, O., Chung, C., Luton, B. K., Diaz, N., Kohnert, C., Consbruck, R., Carter, H., LaCombe, C., Bist, I., Vilaychack, P., Anderson, Z., Xiu, L., Bringas, P., Alarcon, K., Knight, B., Radach, M., Bateman, K., Kopec-Belliveau, G., Chapman, D., Bennett, J., Ventura, A. B., Canales, G. M., Gowda, M., Jackson, K. A., Caguiat, R., Brown, A., Ganini da Silva, D., Guo, Z., Abdulhaqq, S., Klug, L. R., Gander, M., Yapici, E., Meier, J., & Bachas, S.
Venue
bioRxiv (Cold Spring Harbor Laboratory)
Publisher
openRxiv
Published
2023-01-09
OpenAlex
W4313892628
Cited by
82
References
27
Type
posted content
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Unlocking de novo antibody design with generative artificial intelligence. https://app.cochat.ai/papers/10.1101/2023.01.08.523187
The paper
Shanehsazzadeh, A., McPartlon, M., Kasun, G., Steiger, A. K., Sutton, J. M., Yassine, E., McCloskey, C., Haile, R., Shuai, R., Alverio, J., Rakocevic, G., Levine, S., Cejovic, J., Gutierrez, J. M., Morehead, A., Dubrovskyi, O., Chung, C., Luton, B. K., Diaz, N., . . . Bachas, S. (2023). Unlocking de novo antibody design with generative artificial intelligence. bioRxiv (Cold Spring Harbor Laboratory). https://doi.org/10.1101/2023.01.08.523187

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.